https://www.selleckchem.com/pr....oducts/aminooxyaceti
The 5-year overall survival (OS) and event-free survival (EFS) rates were 84.5% and 66.1% as opposed to 82.5% and 46.9%, respectively, for patients in our usual-treatment and treatment-sparing groups.Conclusion We only opted for a treatment-sparing approach for patients with severe disabilities, and their OS was in line with that of children without intellectual disability.What is Known• There are few reports on children/adolescents with cancer and intellectual disability (ID).• It is not clear how to manag
Like
Comment
Share
